BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37505213)

  • 1. PTPN9 dephosphorylates FGFR2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Zhao L; Liu J; Li K; Zhang C; Chen T; Liu Z; Tang Y; Hu X; Shi A; Shu L; Huang S; Lian S; Zhang M; Li H; Sun J; Yu X; Zhang Z; Zhang Z; Xu Y
    Hepatology; 2024 Apr; 79(4):798-812. PubMed ID: 37505213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.
    Liu J; Ren G; Li K; Liu Z; Wang Y; Chen T; Mu W; Yang X; Li X; Shi A; Zhao W; Xu B; Chang J; Guo S; Pan C; Zhou T; Zhang Z; Xu Y
    Cell Death Differ; 2022 Apr; 29(4):818-831. PubMed ID: 34799729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
    Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
    Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
    Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
    Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemigatinib Is Active in Some
    Cancer Discov; 2020 May; 10(5):639. PubMed ID: 32245820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
    Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
    Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
    Merz V; Zecchetto C; Melisi D
    Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy.
    Scheiter A; Keil F; Lüke F; Grosse J; Verloh N; Opitz S; Schlosser S; Kandulski A; Pukrop T; Dietmaier W; Evert M; Calvisi DF; Utpatel K
    Curr Oncol; 2021 Mar; 28(2):1161-1169. PubMed ID: 33800328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicogenomic Analysis of
    Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
    Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement].
    Delaye M; Pernot S
    Bull Cancer; 2021 May; 108(5):446-447. PubMed ID: 33931169
    [No Abstract]   [Full Text] [Related]  

  • 17. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemigatinib: First Approval.
    Hoy SM
    Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
    Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
    Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
    Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
    Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.